Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer’s disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.
This page contains content from the copyrighted Wikipedia article "Radequinil"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
